Alvotech (ALVOW)
| Market Cap | 1.77B -26.3% |
| Revenue (ttm) | 494.61M -4.4% |
| Net Income | -179.59M |
| EPS | -0.61 |
| Shares Out | 356.82M |
| PE Ratio | n/a |
| Forward PE | 21.02 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 0.3799 |
| Day's Range | n/a |
| 52-Week Range | 0.1188 - 3.0000 |
| Beta | 0.18 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2026 |
About ALVOW
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat variou... [Read more]
News
Alvotech to present at upcoming investor conferences in September
REYKJAVIK, ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide...
Alvotech initiated with a Buy at BofA
BofA initiated coverage of Alvotech (ALVO) with a Buy rating and $7 price target The firm sees attractive risk/reward as Alvotech’s multi-year investments begins to translate into a “higher-quality co...
Alvotech enters licensing, commercialization agreement with Lotus Pharmaceutical
Alvotech (ALVO) announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical covering two of Alvotech’s candidates in the United States and selected Asian markets: AVT34, ...
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for pati...
Alvotech Earnings Call Transcript: Q2 2026
H1 2026 saw revenue of $212M and adjusted EBITDA of $47M, impacted by manufacturing slowdowns for facility improvements, but manufacturing returned to planned levels by Q2 end. Five biosimilars now contribute to revenue, and guidance for 2026 is reaffirmed at $650–700M revenue and $180–220M adjusted EBITDA.
Alvotech Earnings release: Q2 2026
Alvotech released its Q2 2026 earnings on August 20, 2026, summarizing the period's financial results.
Alvotech Slides: Q2 2026
Alvotech has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 20, 2026.
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
REYKJAVIK, ICELAND (August 19, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar med...
Alvotech initiated with an Outperform at Evercore ISI
Evercore ISI initiated coverage of Alvotech (ALVO) with an Outperform rating and no price target The firm believes that Alvotech’s recent FDA inspection classification of VAI has “majorly derisked” th...
Alvotech to Report Financial Results for H1 2026
REYKJAVIK, ICELAND (August 10, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for pa...
Alvotech announces successful closure of FDA inspection of manufacturing facility
REYKJAVIK, Iceland, July 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar me...
Transactions of Managers and Closely Associated Persons
Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the pledging...
Alvotech further strengthens liquidity by securing term loan facility of $75 million
REYKJAVIK, ICELAND (July 1, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, to...
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medi...
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
REYKJAVIK, Iceland, June 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of...
Alvotech $152M Spot Secondary priced at $3.75
The company priced 22.6M ordinary shares at $3.75 and 17.8M ordinary shares in a private placement. BofA, Jefferies and Evercore ISI acted as joint book running managers for the offering.
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
REYKJAVIK, ICELAND (June 16, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medi...
Alvotech TBA Spot Secondary; price range $3.75-$undefined
BofA, Jefferies and Evercore ISI are acting as joint book running managers for the offering.
Alvotech announces termination of ATM Prospectus Supplement with Jefferies
On June 15, Alvotech (ALVO) notified Jefferies (JEF) that it was suspending its use of and terminating the prospectus supplement related to the potential issuance from time to time of…
Alvotech Transcript: UBS Virtual Generics and Biosimilars Day
The company is positioned for significant growth with a robust biosimilar pipeline, strong global partnerships, and recent regulatory progress. Key launches for SIMPONI, EYLEA, and Entyvio are on track, supported by expanded manufacturing and a focus on limited-competition markets.
Alvotech Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is at a pivotal stage, having addressed FDA facility concerns and resubmitted key BLAs, with multiple U.S. launches expected by year-end. Its pipeline targets high-value biosimilars like Entyvio and Eylea, supported by expanded manufacturing and a strategy to be first-to-market in major categories.
Alvotech announces FDA acceptance of AVT16 BLA for review
Alvotech (ALVO) announced that the FDA has accepted for review a biologics license application, or BLA, for AVT16, a proposed interchangeable biosimilar to Entyvio lyophilized vial for intravenous adm...
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for pati...
Alvotech Transcript: Jefferies Global Healthcare Conference 2026
The company is accelerating U.S. launches with recent FDA resubmissions and expects five products on the U.S. market by year-end. Expanded manufacturing through a Fujifilm partnership supports a robust pipeline, with first-to-market ambitions for key biosimilars like ENTYVIO and high-dose Eylea. 2026 guidance projects strong revenue and EBITDA growth.
Alvotech resubmits AVT05 BLAs to FDA
Alvotech (ALVO) announced the resubmission to the FDA of biologics license applications, or BLAs, for AVT05, a proposed biosimilar to Simponi and Simponi Aria, and AVT06, a proposed biosimilar to…